Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soo Yoon

Showing results (1071-1080 of 1,104) with videos related to

Pageof 111
Sort By:
American Journal of Hematology|October 19, 2012
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patientsInho Kim, Youngil Koh, Sung-Soo Yoon, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Cancer Research and Treatment|January 3, 2023
Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, et al.
International Journal of Hematology|September 5, 2020
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasoneHo Sup Lee, Kihyun Kim, Je-Jung Lee, et al.
The Lancet. Haematology|July 30, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 studyAaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, et al.
Science (New York, N.Y.)|May 21, 2005
Patient-specific embryonic stem cells derived from human SCNT blastocystsWoo Suk Hwang, Sung Il Roh, Byeong Chun Lee, et al.
Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
Annals of Hematology|December 25, 2019
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)Jae-Cheol Jo, Ho Sup Lee, Kihyun Kim, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Annals of Hematology|May 22, 2026
Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemiaSeok Lee, Hyeoung-Joon Kim, June-Won Cheong, et al.
Pageof 111

Showing results (1071-1080 of 1,104) with videos related to

Sort By:
Pageof 111
American Journal of Hematology|October 19, 2012
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patientsInho Kim, Youngil Koh, Sung-Soo Yoon, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Cancer Research and Treatment|January 3, 2023
Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, et al.
International Journal of Hematology|September 5, 2020
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasoneHo Sup Lee, Kihyun Kim, Je-Jung Lee, et al.
The Lancet. Haematology|July 30, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 studyAaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, et al.
Science (New York, N.Y.)|May 21, 2005
Patient-specific embryonic stem cells derived from human SCNT blastocystsWoo Suk Hwang, Sung Il Roh, Byeong Chun Lee, et al.
Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
Annals of Hematology|December 25, 2019
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)Jae-Cheol Jo, Ho Sup Lee, Kihyun Kim, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Annals of Hematology|May 22, 2026
Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemiaSeok Lee, Hyeoung-Joon Kim, June-Won Cheong, et al.
Pageof 111